Shilpa Medicare Subsidiary Partners Gate2Brain for Brain Cancer Therapy
Shilpa Medicare's wholly-owned subsidiary, Shilpa Biocare Private Limited, has entered into a strategic equity partnership with Gate2Brain, S.L., acquiring a 30.4% stake. Gate2Brain is a biotechnology company focused on developing peptide-based delivery systems for central nervous system diseases. This partnership involves an investment of €7 million, comprising a €0.5 million cash infusion, €5.5 million for services, and €1 million for project development. Shilpa Biocare will also serve as the CMC, manufacturing, and regulatory partner for Gate2Brain's lead candidate, G2B-002, an oncology asset targeting brain cancer with Orphan Drug Designation from the U.S. FDA and EMA. The collaboration aims to advance G2B-002 towards first-in-human studies, anticipated by FY28, and leverage Gate2Brain's proprietary MiniAp4 peptide shuttle platform for other CNS therapeutic categories. This marks Shilpa Medicare's fourth such strategic equity partnership, aligning with its strategy to invest in high-potential therapeutic assets.
Key Highlights
- Shilpa Medicare subsidiary invests €7M for 30.4% stake in Gate2Brain.
- Partnership focuses on advancing G2B-002, a novel brain cancer therapy.
- Shilpa to provide CMC, manufacturing, and regulatory support.
- G2B-002 has Orphan Drug Designation from FDA and EMA.
- First-in-human trials for G2B-002 expected by FY28.
Price Impact
More from SHILPAMED